Clinical Trials
18
Trial Phases
3 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (16 trials with phase data)• Click on a phase to view related trials
A Study to Assess the Long-term Safety Outcomes in Patients Previously Treated With RP1, RP2, or RP3
- Conditions
- MelanomaMetastatic MelanomaAdvanced Solid TumorHepatocellular Carcinoma
- First Posted Date
- 2025-03-20
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Replimune Inc.
- Target Recruit Count
- 50
- Registration Number
- NCT06887348
An Expanded Access Program for VO (RP1) in Combination With Nivolumab in Patients With Advanced Melanoma
- Conditions
- Advanced Melanoma
- First Posted Date
- 2024-09-19
- Last Posted Date
- 2025-03-19
- Lead Sponsor
- Replimune Inc.
- Registration Number
- NCT06590480
A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma
- Conditions
- Metastatic Uveal Melanoma
- Interventions
- First Posted Date
- 2024-09-03
- Last Posted Date
- 2025-08-01
- Lead Sponsor
- Replimune Inc.
- Target Recruit Count
- 280
- Registration Number
- NCT06581406
- Locations
- 🇺🇸
HonorHealth Research Insisute, Scottsdale, Arizona, United States
🇺🇸UC San Diego Moores Cancer Center, La Jolla, California, United States
🇺🇸The Angeles Clinic and Research Institute, Los Angeles, California, United States
VO and Nivolumab vs Physician's Choice in Advanced Melanoma That Progressed on Anti-PD-1 & Anti-CTLA-4 Drugs (IGNYTE-3)
- Conditions
- Advanced Melanoma
- Interventions
- Drug: Single-agent chemotherapy
- First Posted Date
- 2024-02-16
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- Replimune Inc.
- Target Recruit Count
- 400
- Registration Number
- NCT06264180
- Locations
- 🇺🇸
Memorial Cancer Institute at Memorial Regional Hospital, Hollywood, California, United States
🇺🇸Sutter Medical Group, Sacramento, California, United States
🇺🇸University of Colorado Hospital - Anschutz Cancer Pavilion, Aurora, Colorado, United States
Study of RP3 in Combination With Nivolumab and Other Therapy in Patients With Locoregionally Advanced or Recurrent SCCHN
- Conditions
- Locally Advanced Head and Neck Squamous Cell CarcinomaRecurrent Head and Neck Squamous Cell CarcinomaSquamous Cell Carcinoma of Head and Neck
- Interventions
- Other: CCRT(concurrent chemoradiation therapy)Other: carboplatin and paclitaxel
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2025-03-11
- Lead Sponsor
- Replimune Inc.
- Registration Number
- NCT05743270
- Locations
- 🇺🇸
University of California San Diego, UCSD, La Jolla, California, United States
🇺🇸USC Norris Comprehensive Cancer Center, Los Angeles, California, United States
🇺🇸UCLA Medicine Division of Hematology-Oncology, Los Angeles, California, United States
- Prev
- 1
- 2
- 3
- Next